Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Centene director Coughlin sells $67,382 in company stock

Published 05/25/2024, 05:32 AM
CNC
-

Centene Corp's (NYSE:CNC) director, Christopher J. Coughlin, has sold a total of $67,382 worth of company stock, according to a recent SEC filing. The transaction involved 878 shares of Centene's common stock at a price of $76.745 each.

The sale took place on May 14, 2024, and following the transaction, Coughlin's directly owned stock in the company was reduced to zero. However, it's important to note that his indirect ownership through family trusts, where he serves as the sole trustee, remains significant. The filing also revealed that Coughlin's overall holdings include 25,503.926 shares, which accounts for shares of restricted stock units that are subject to vesting requirements.

Investors often keep a close eye on insider transactions as they can provide insights into the executives' perspectives on the company's current valuation and future prospects. In the case of Centene, a leading provider of hospital and medical service plans, such transactions are of particular interest given the company's impact on the healthcare sector.

Centene Corp has not provided any public comments regarding the transaction at this time. The details of the sale are publicly available through the SEC's filing system for those interested in the specifics of the transaction.

InvestingPro Insights

In light of the recent insider sale by Centene Corp's (NYSE:CNC) director Christopher J. Coughlin, it's noteworthy to consider current metrics and insights that could influence investor perception of the company's stock. According to InvestingPro data, Centene boasts a market capitalization of $39.82 billion and operates with a moderate level of debt. The company's Price/Earnings (P/E) ratio stands at 14.71, which adjusts to an even more attractive 13.04 when considering the last twelve months as of Q1 2024. This could signal that the stock is trading at a low valuation relative to near-term earnings growth, an InvestingPro Tip that suggests the company's shares might be undervalued.

Additionally, Centene's revenue for the last twelve months as of Q1 2024 is reported at $142.8 billion, reflecting a steady growth rate of 4.28%. Another InvestingPro Tip highlights that 8 analysts have revised their earnings upwards for the upcoming period, which may indicate positive sentiment about the company's future performance. Moreover, the company's stock is known for low price volatility, which could appeal to investors looking for stability in the Healthcare Providers & Services industry.

For those considering a deeper dive into Centene's financials and future outlook, InvestingPro offers a wealth of detailed analysis and additional tips. There are 9 more InvestingPro Tips available for Centene, which can be accessed at https://www.investing.com/pro/CNC. Interested investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing an opportunity to leverage advanced tools and insights for informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.